Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
Liver Failure (Hepatic Insufficiency) - Drug Profiles
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
Jun 24, 2022: Versantis presents new VS-01 data at The Intertiol Liver Congress 2022
Nov 15, 2021: Versantis to present positive phase 1b data at AASLD for VS-01 in patients with decompensated Cirrhosis
Nov 09, 2021: GENFIT announces first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program
Feb 01, 2021: Creative Medical Technology Holdings identifies and files patent on novel mechanism of ImmCelz therapeutic activity
Jun 29, 2020: GoLiver Therapeutics receives a positive scientific advice from the European Medicines Agency (EMA) on its clinical development and biomanufacturing strategy for acute liver failure
Jan 08, 2020: Promethera announces initiation of phase 2b DHELIVER study of HepaStem in patients with acute-on-chronic liver failure (ACLF)
Dec 31, 2019: Versantis’ main patent allowed in the USA.
Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world’s first stem cell therapy trial using HepaStem in acute-on-chronic liver failure
May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world’s first liver stem cell therapy in late-stage SH patients
Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world’s first stem cell clinical trial in ACLF at The Intertiol Liver Congress/ EASL 2019
Mar 31, 2019: Versantis: Main patent for VS-01 granted in two additiol countries.
Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF
Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April
Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Cada
Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Desigtion to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Liver Failure (Hepatic Insufficiency) - Dormant Projects, 2022
Liver Failure (Hepatic Insufficiency) - Dormant Projects, 2022 (Contd..1)
Liver Failure (Hepatic Insufficiency) - Discontinued Products, 2022